China's Cell Therapy Industrialization Accelerates: Dual Drivers of Regulation and Clinical Practice

Introduction

In recent years, cell therapy, as a disruptive medical technology, has been transitioning from the laboratory to clinical practice and the market. China's development in this field has been particularly rapid, not only leading globally in the number of clinical trials but also continuously refining its regulatory system. As of 2025, the National Medical Products Administration (NMPA) has approved multiple CAR-T cell therapy products for market entry, covering indications such as hematologic malignancies and other refractory diseases. Meanwhile, pipelines including mesenchymal stem cells and gene-edited cells have advanced to late-stage clinical trials. For international patients, understanding China's progress in cell therapy industrialization means seizing more treatment options and opportunities to reduce costs. This article systematically reviews the dual-driven landscape of regulation and clinical practice, offering practical recommendations.

Regulatory Framework: From "Case-by-Case Approval" to "Standardized Market Authorization"

Over the past decade, China's cell therapy regulation has undergone significant transformation. In the early stages, a "third-class medical technology" model was used for case-by-case approvals, leading to slow clinical translation. Starting in 2020, the NMPA explicitly classified cell therapy products as drugs, issuing a series of documents such as the "Technical Guidelines for Research and Evaluation of Cell Therapy Products" and establishing a "tacit approval" system, significantly shortening clinical trial approval times. In 2023, the "Technical Guidelines for Pharmaceutical Research and Evaluation of Human Stem Cell Products" were released, further refining development standards. In 2025, the revised "Drug Administration Law" clarified accelerated approval pathways for innovative products like cell therapies, implementing rolling reviews for breakthrough therapies. These measures have moved China's cell therapy regulation from a "gray area" to a "transparent track," laying the institutional foundation for industrialization.

Clinical Progress: From Hematologic Malignancies to Solid Tumors and Regenerative Medicine

China accounts for nearly one-third of global cell therapy clinical trials, particularly in the CAR-T field, where four products have been approved, such as Axicabtagene Ciloleucel Injection and Relmacabtagene Autoleucel Injection, targeting indications like relapsed/refractory large B-cell lymphoma. In 2024, the first domestic BCMA-targeted CAR-T product was approved for multiple myeloma, with efficacy data comparable to global benchmark products, achieving a complete response rate exceeding 70%. In more cutting-edge areas, such as universal CAR-T and dual-target CAR-T, Chinese teams have published multiple high-impact studies, and breakthroughs have been made in solid tumor treatment, such as Claudin18.2 CAR-T improving the objective response rate in gastric cancer to 48%. In the field of mesenchymal stem cells, Phase III clinical trials for indications like knee osteoarthritis and diabetic foot have been completed, with one multicenter study showing an 85% improvement in joint function at 12 months post-treatment. Additionally, retinal pigment epithelial cells derived from induced pluripotent stem cells (iPSCs) for treating macular degeneration have undergone the first transplantation at a hospital affiliated with Sun Yat-sen University, with significant visual improvement at 6 months post-surgery. These advances not only benefit domestic patients but also provide a platform for international medical collaboration.

Industrialization Pathway: From "Laboratory" to "Scaled Production"

Industrialization is key to the clinical application of cell therapy. China has invested heavily in cell manufacturing, quality control, and cold-chain transportation. Currently, multiple GMP-compliant cell manufacturing centers have been established, such as the Shanghai Zhangjiang Cell Industry Park, with an annual production capacity of tens of thousands of doses. Cost control is a core advantage: compared to foreign treatment costs often exceeding hundreds of thousands of dollars, CAR-T pricing in China ranges from approximately 1 to 1.5 million RMB, with some products reduced to around 500,000 RMB after inclusion in medical insurance negotiations. In 2025, Shanghai took the lead in including CAR-T in city-level customized commercial insurance, covering 55 specialty drugs. Industrialization is also reflected in the improvement of the supply chain: the domestic localization rate of upstream reagents and consumables increased from 30% in 2020 to 60% in 2025, while midstream companies such as JW Therapeutics and Legend Biotech are accelerating global expansion. However, scaled production still faces challenges, such as reliance on imported automated equipment and insufficient standardization of quality control, but China is promoting industry consensus through the "Cell Therapy Industry Alliance." For patients, this means increased treatment accessibility, but it is still essential to choose qualified institutions.

International Patient Perspective: How to Access China's Cell Therapy System

For overseas patients, cell therapy in China is attractive due to shorter waiting times, lower clinical trial entry barriers (some trials accept international patients), and cost advantages. However, seeking medical treatment in China requires attention to the following process: first, obtain a medical evaluation from a partner hospital in China, providing complete translated medical records; second, confirm whether the treatment product has received NMPA approval or clinical trial permission; finally, apply for a medical visa and reserve at least 3 weeks for comprehensive examinations and treatment preparation. We strongly recommend obtaining official guidance through Contact Us to ensure compliance. Additionally, some trial programs may offer free treatment, but strict enrollment criteria must be met. For example, a hospital in Shanghai is recruiting international patients for solid tumor CAR-T trials, requiring at least 2 prior lines of therapy and no severe organ dysfunction. Medical cost estimates can be referenced using the Cost Estimator tool, but individual differences should be noted. Overall, the accessibility and cost-effectiveness of cell therapy in China are reshaping the global medical landscape.

Recommendations for International Patients

First, determine whether your indication falls within the scope of cell therapy, especially hematologic malignancies, specific solid tumors, or degenerative diseases. Second, obtain authoritative information to avoid intermediary misinformation, and always verify institutional qualifications through Official Medical Services channels. Third, assess your budget, including treatment costs, hospitalization fees, translation, and travel expenses, and recommend reserving a 20% contingency fund. Fourth, understand the risks and benefits of clinical trials, and consult an independent medical advisor before signing informed consent. Fifth, maintain continuous follow-up with your doctor in China, as some cell therapies require long-term monitoring. We encourage patients to actively participate in clinical research, which is an effective way to access cutting-edge treatments and reduce costs. For professional evaluation, feel free to submit your medical records through Contact Us to receive a personalized plan. The threshold for cell therapy in China is lowering, but scientific decision-making remains paramount.